Robert J Oldham

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Ankylosing Spondylitis

Top Venues

Journal of immunology (Baltimore, Md. : 1950)

Antibodies (Basel, Switzerland)

Journal for immunotherapy of cancer

Communications biology

This page only lists publications with an associated author ORCID identifier.

Publications

Joshua M Sopp, Shirley J Peters, Tania F Rowley, Robert J Oldham, Sonya James, Ian Mockridge, Ruth R French, Alison Turner, Stephen A Beers, David P Humphreys, Mark S Cragg
On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation. Communications biology 4 (1) (2021)
Robert J Oldham, C Ian Mockridge, Sonya James, Patrick J Duriez, H T Claude Chan, Kerry L Cox, Vicentiu A Pitic, Martin J Glennie, Mark S Cragg
FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion. Journal for immunotherapy of cancer 8 (1) (2021)
Rena Liu, Robert J Oldham, Emma Teal, Stephen A Beers, Mark S Cragg
Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment. Antibodies (Basel, Switzerland) 9 (4) (2020)
Richard J Stopforth, Robert J Oldham, Alison L Tutt, Patrick J Duriez, H T Claude Chan, Brock F Binkowski, Chad Zimprich, Dun Li, Philip G Hargreaves, Mei Cong, Venkat Reddy, Maria J Leandro, Geraldine Cambridge, Anja Lux, Falk Nimmerjahn, Mark S Cragg
Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB. Journal of immunology (Baltimore, Md. : 1950) 200 (5) (2018)
Adam Palazzo, Sylvia Herter, Laura Grosmaire, Randy Jones, Christian R Frey, Florian Limani, Marina Bacac, Pablo Umana, Robert J Oldham, Michael J E Marshall, Kerry L Cox, Anna H Turaj, Mark S Cragg, Christiane Neumann, Matthew J Carter, Stacey Tannheimer
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. Journal of immunology (Baltimore, Md. : 1950) 200 (7) (2018)